The economic proof
The morphine reduction tracked with a shorter stay. In cardiac surgery, that's tens of thousands of dollars per patient.
TL;DR
Alongside the 70% morphine reduction, the CABG study found approximately a two-day shorter median hospital length of stay. In cardiac surgery, where an inpatient day costs roughly $5,000–10,000, this is the finding that turns a comfort story into an economics story — and the one that gets a hospital administrator's attention.
The Baylor / DeBakey VA cardiac study found approximately a two-day shorter median hospital length of stay in the tPEMF-treated group, alongside the 70% morphine reduction. These two findings are related: lower opioid burden means faster return to ambulation, less respiratory depression, fewer opioid-related complications — all of which are immediate determinants of discharge readiness.
The average cost of a cardiac surgery inpatient day in a US academic medical center ranges from roughly $5,000 to $10,000 depending on ICU requirements and payer mix. Two fewer days represents $10,000–20,000 in facility cost per patient. Multiplied across a cardiac service line that performs 200–500 CABG procedures annually, the aggregate savings potential runs into the millions — from a $500 device. That arithmetic is why length-of-stay is the metric that gets hospital finance departments interested.
Hospital-acquired complications — infection, delirium, DVT — rise with length of stay. Shorter stays are not just cheaper; they reduce exposure to a risk environment. A patient who is mobile, not sedated by opioids, and able to demonstrate recovery earlier is a patient who goes home sooner to a lower-risk environment. The hospital benefits economically; the patient benefits clinically. The alignment of those interests is unusual and is part of what makes the length-of-stay finding especially compelling.
Length of stay was measured from surgical procedure to discharge order in calendar days, with median as the summary statistic. Median is appropriate for this endpoint because hospital stay distributions are right-skewed — a few very prolonged stays would inflate a mean. The two-day shift in median reflects a real change in the central tendency of the distribution, not simply elimination of outliers. For a hospital administrator evaluating device adoption, median length of stay is one of the most directly legible operational metrics available.
A cardiac surgery program adding tPEMF to its post-CABG protocol for 30 patients per year could expect approximately 60 inpatient days recovered (30 patients × 2 days). At $7,500 per inpatient day (midpoint of the $5,000–$10,000 range), that is $450,000 in facility-cost reduction annually. Against a device cost of approximately $500 per patient ($15,000 total at 30 patients), the return on device cost is roughly 30:1 — a calculation that changes the framing from 'is this worth the budget?' to 'why haven't we implemented this yet?'
Sources & references
Related